Ocular Therapeutix (OCUL) Debt to Equity (2016 - 2026)
Ocular Therapeutix has reported Debt to Equity over the past 14 years, most recently at $0.12 for Q1 2026.
- For Q1 2026, Debt to Equity fell 52.38% year-over-year to $0.12; the TTM value through Mar 2026 reached $0.12, down 52.38%, while the annual FY2025 figure was $0.11, 49.81% down from the prior year.
- Debt to Equity for Q1 2026 was $0.12 at Ocular Therapeutix, up from $0.11 in the prior quarter.
- Over five years, Debt to Equity peaked at $8.29 in Q3 2023 and troughed at $0.11 in Q4 2025.
- A 5-year average of $1.35 and a median of $0.27 in 2025 define the central range for Debt to Equity.
- Biggest five-year swings in Debt to Equity: skyrocketed 1876.8% in 2023 and later crashed 97.68% in 2024.
- Year by year, Debt to Equity stood at $0.71 in 2022, then grew by 1.12% to $0.72 in 2023, then tumbled by 69.91% to $0.22 in 2024, then plummeted by 49.81% to $0.11 in 2025, then rose by 13.65% to $0.12 in 2026.
- Business Quant data shows Debt to Equity for OCUL at $0.12 in Q1 2026, $0.11 in Q4 2025, and $0.27 in Q3 2025.